Guidelines for the management of rheumatoid arthritis: 2002 Update

Authors

  • American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines

    Corresponding author
    1. American College of Rheumatology, 1800 Century Place, Suite 250, Atlanta, GA 30345
    • 1800 Century Place, Suite 250, Atlanta, GA 30345
    Search for more papers by this author
    • Members of the American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines are as follows. C. Kent Kwoh, MD, Chair: University of Pittsburgh, Pittsburgh, Pennsylvania; Larry G. Anderson, MD: Rheumatology Associates, Portland, Maine; Jerry M. Greene, MD: VA Medical Center, West Roxbury, Massachusetts; Dorothy A. Johnson, DNSc, FNP: Los Angeles County + University of Southern California Medical Center, Los Angeles; James R. O'Dell, MD: University of Nebraska Medical Center, Omaha; Mark L. Robbins, MD, MPH: Harvard Vanguard Medical Associates, Boston, Massachusetts; W. Neal Roberts, Jr., MD: Medical College of Virginia, Richmond; Robert W. Simms, MD: Boston University Arthritis Center, Boston, Massachusetts; Robert A. Yood, MD: The Fallon Clinic, Worcester, Massachusetts.


  • Dr. Kwoh has been a consultant to Wyeth-Ayerst Laboratories and Immunex (both in 1998) and has served as a member of the advisory boards for Aventis Pharmaceuticals (in 1999) and Pfizer (2001). Dr. Anderson has served as a member of the medical advisory board for Merck & Company. Dr. Greene is a shareholder (not major equity) in Johnson & Johnson and Merck & Company. Dr. O'Dell has served on the speaker's bureaus of Aventis Pharmaceuticals, Pharmacia & Upjohn, and Merck & Company, and has served as a consultant to Amgen, Centocor, Immunex, and Bristol-Myers Squibb. Dr. Roberts has received funding for educational activities and clinical trials from Sanofi, Pfizer, and G. D. Searle & Company (during the 1990s; total funding less than $100,000), but currently receives no industry funding. Dr. Simms has served on the speaker's bureau of Merck & Company and has received grant support from Aventis Pharmaceuticals. Dr. Yood is an investigator of an ongoing research trial of anti–tumor necrosis factor α and interleukin-1 receptor antagonist sponsored by Amgen.

  • The American College of Rheumatology is an independent, professional, medical and scientific society which does not guarantee, warrant, or endorse any commercial product or service.

Ancillary